drugset / Trial / NCT00845676
Treatment of Acute Hepatitis C Virus in HIV Co-Infection
Phase 4
Completed
21 enrolled
University of California, San Francisco
California HIV/AIDS Research Program · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is designed to test the hypothesis that treatment of hepatitis C virus (HCV) infection during the first 6 months after acquiring HCV among people who already have pre-existing HIV infection will result in improved responses to HCV therapy with a shorter duration of infection.
Timeline
- Start
- 2008-03
- Primary completion
- 2010-12
- Completion
- 2013-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Peginterferon alfa-2a | Protein / enzyme biologic | 180 ug | Subcutaneous |
| Subject | Ribavirin | Small molecule | 1000 mg | — |
| Subject | Ribavirin | Small molecule | 1200 mg | — |